Earnings Preview: What to Expect From Gilead Sciences’ Report

Gilead Sciences, Inc. (GILD), based in Foster City, California, has a market capitalization of approximately $187.4 billion. The biopharmaceutical company discovers, develops, and delivers innovative medicines for serious diseases, with research focused on virology, oncology, and inflammation.

GILD is set to report its Q3 earnings soon. Ahead of the release, analysts expect the company to report diluted EPS of $2.16, down 12.6% from $2.47 in the year-ago quarter. However, GILD has exceeded Wall Street’s EPS estimates in each of the past four quarters, highlighting its consistent earnings performance.

For fiscal 2026, analysts expect GILD to report a loss of $0.47 per share, a sharp 105.8% decline from $8.15 per share in fiscal 2025. However, GILD’s EPS is projected to rebound 2,208.5% annually to $9.90 in fiscal 2027.

GILD stock has risen 28.4% over the past 52 weeks, outperforming both the S&P 500 Index ($SPX), which gained 19.2%, and the State Street Health Care Select Sector SPDR ETF (XLV), which gained 21% over the same period.

Gilead Sciences’ strong performance reflects investor interest in its long-term growth prospects, supported by continued investment in research and development and efforts to strengthen its drug pipeline. The company recently opened a 182,000-square-foot research center at its Foster City headquarters, expanding its capabilities in oncology, inflammation, and research data science. This investment underscores Gilead’s commitment to advancing innovative medicines and addressing significant unmet medical needs.

Further bolstering its pipeline prospects, on October 5, Gilead announced a second two-year extension of its research collaboration with Nurix Therapeutics, Inc. (NRIX) for an undisclosed oncology program. The collaboration has already advanced GS-6791, an oral IRAK4 degrader, into Phase 1 clinical development. Although the extended program’s potential remains uncertain, successful development could strengthen Gilead’s oncology portfolio and create additional long-term growth opportunities.

Analysts remain bullish on GILD, with a consensus “Strong Buy” rating. Of the 30 analysts covering the stock, 21 recommend a “Strong Buy,” two suggest a “Moderate Buy,” and seven rate it a “Hold.” The average analyst price target of $160.07 represents a 6.4% premium to the current share price.

On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.